Guardant Health (GH)
(Delayed Data from NSDQ)
$31.75 USD
-1.61 (-4.83%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $31.76 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GH 31.75 -1.61(-4.83%)
Will GH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GH
Merus N.V. (MRUS) Reports Q2 Loss, Lags Revenue Estimates
Guardant Health (GH) Moves 6.9% Higher: Will This Strength Last?
GH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Guardant Health (GH) Just Overtook the 20-Day Moving Average
Guardant Health (GH) Now Trades Above Golden Cross: Time to Buy?
Guardant Health (GH) Recently Broke Out Above the 200-Day Moving Average
Other News for GH
Vanguard Health Care Fund Amplifies Stake in Novo Nordisk A/S
Guardant launches Shield colorectal cancer test in U.S.
Guardant launches newly approved colorectal cancer test in U.S.
Guardant Health?s FDA-approved Shield? Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer
Guardant Health Outcomes Model Confirms the Public Health Importance of Enhanced Colorectal Cancer Screening Outcomes with High Adherence Strategies